Infectious Disease and Microbiology – Burkholderia mallei

Overview

Burkholderia mallei is an aerobic Gram-negative bacillus that causes glanders, an uncommon zoonotic infection primarily affecting horses, donkeys, and mules. Human disease is rare and usually follows close occupational or environmental exposure to infected equine animals. Infection can range from localized skin disease to severe pneumonia and life-threatening sepsis.

Microbiology

B. mallei is a small Gram-negative bacillus belonging to the genus Burkholderia. It is closely related to Burkholderia pseudomallei, the organism responsible for melioidosis.

The two organisms cannot reliably be distinguished by routine microscopic examination alone, so definitive identification requires specialized laboratory methods.

Incubation Period

The incubation period is generally short, with symptoms commonly developing approximately 1–5 days after exposure, although the clinical timing can vary according to the route and intensity of exposure.

Epidemiology

B. mallei primarily causes disease in equine animals, particularly horses, donkeys, and mules. Humans are accidental hosts and usually acquire infection through direct contact with infected animals or their contaminated secretions.

Historically, human glanders has been reported in parts of Asia, Africa, the Middle East, and Central and South America. Human cases are now uncommon because of improved veterinary surveillance and control of glanders among equine populations.

People with frequent occupational contact with horses and other equids are at greatest risk, including veterinarians, animal handlers, farmers, and laboratory personnel working with the organism.

Transmission and Pathogenesis

Human infection generally occurs when contaminated animal secretions enter through broken skin or mucous membranes. Infection may also occur through inhalation of contaminated droplets or aerosols.

Following entry into the body, the organism can produce localized infection or spread through the lymphatic and bloodstream systems. Dissemination can lead to multiple abscesses, pneumonia, bacteremia, and septic illness.

Clinical Infections

The characteristic disease caused by B. mallei is glanders. Clinical presentation depends partly on the route of infection.

Cutaneous glanders may begin with papules, pustules, or ulcerative lesions at the inoculation site. Regional lymphatic involvement can produce lymphangitis and suppurative lymphadenitis.

Pulmonary glanders can develop after inhalation or hematogenous dissemination. Patients may experience fever, cough, chest pain, dyspnea, and pneumonia.

Septicemic or disseminated glanders represents severe systemic infection and may cause high fever, hypotension, multiple organ involvement, abscess formation, and sepsis.

Diagnosis

Direct microscopic examination of wound or lesion exudates is generally insensitive, and the organism may not be readily identified.

Furthermore, microscopic morphology cannot reliably differentiate B. mallei from the closely related B. pseudomallei.

Definitive diagnosis is primarily based on culture and specific laboratory identification of the organism. Serologic testing has also been used as supportive evidence in appropriate epidemiologic settings.

Because B. mallei poses an important laboratory-acquired infection risk, the laboratory should be informed promptly when glanders is suspected so that appropriate biosafety procedures can be followed.

Treatment

Clinical evidence regarding the optimal antimicrobial regimen for glanders is limited because human infection is exceptionally rare.

Historically, combinations involving imipenem and doxycycline have been used. Other agents with laboratory activity against B. mallei include ceftazidime and certain other antimicrobials.

Management of suspected or confirmed glanders should involve infectious disease and public health specialists because treatment generally requires prolonged antimicrobial therapy and careful assessment for disseminated infection.

Surgical Management

Antibiotic therapy may need to be combined with surgical treatment when localized collections of infection develop.

In particular, suppurative lymphadenitis or abscesses may require drainage or other appropriate surgical management in addition to systemic antimicrobial therapy.

Prevention

The most effective preventive strategy is control and eradication of glanders in equine animals. Individuals handling potentially infected horses, donkeys, or mules should use appropriate protective measures and avoid direct exposure to animal secretions.

Suspected human infection also requires appropriate infection-control and public health precautions. Although person-to-person transmission is uncommon, exposure to infected secretions should be minimized.

High-Yield Clinical Pattern

Consider glanders when a patient with significant horse, donkey, or mule exposure develops an acute febrile illness accompanied by ulcerative skin lesions, lymphadenitis, pneumonia, or sepsis.

The key organism is Burkholderia mallei, and definitive diagnosis requires specialized culture or laboratory identification rather than microscopy alone.

Exam Essentials

Organism: Burkholderia mallei

Microbiology: Aerobic Gram-negative bacillus

Major disease: Glanders

Primary reservoir: Horses, donkeys, and mules

Transmission: Contact with infected animals or their secretions; inhalational exposure may occur

Typical incubation: Approximately 1–5 days

Clinical forms: Cutaneous/lymphatic, pulmonary, and septicemic or disseminated disease

Diagnosis: Culture with specific organism identification; serology may provide supportive evidence

Important distinction: Microscopy alone cannot reliably distinguish B. mallei from B. pseudomallei

Treatment: Requires specialist-guided antimicrobial therapy; regimens may include agents such as ceftazidime or a carbapenem followed by appropriate eradication therapy

Surgery: May be necessary for abscesses or suppurative lymphadenitis

Prevention: Control of glanders in equine animals and appropriate precautions during animal and laboratory exposure.